Abstract 3241: Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison of Serial Angiographic Follow-Up with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-Eluting Stent: Multicenter Registry in Asia
Background and Purpose: Drug-eluting stent have been proven to be effective in reducing restenosis in patients with chronic coronary total occlusion (CTO). However, no studies comparing different drug-eluting stents in this complex subset are yet available. The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES) and Tacrolimus-eluting stent (TES) on the outcome of patients with CTO.
Methods: A prospective analysis of 977 patients with 1065 CTOs (396 SES, 526 PES, 79 ZES, 64 TES) in five high volume Asian centers after successful recanalization of CTO (defined as TIMI flow grade 0 and the age of occlusion was more than 3 months) was performed. The study endpoints were 30 days and 9 months major adverse cardiac events (MACE), 9 months angiographic restenosis and target lesion revascularization (TLR).
Results: The baseline clinical characteristics between 4 groups are similar. See table⇓ for clinical results.
Conclusion: The use of drug-eluting stents in patients with CTO was safe with low acute complication. Patients treated with SES showed lesser rate of restenosis compared with other drug-eluting stents.